Use of Baricitinib is Safe and Effective in Moderate-to-Severe Atopic Dermatitis, Study Reveals

A recent study has revealed that the use of the oral selective Janus kinase 1/Janus kinase 2 inhibitor baricitinib is effective against moderate-to-severe atopic dermatitis or AD, with no new safety concerns or issues over 16 weeks.

Photo: Atopic Dermatitis | InStyleHealth


Researchers evaluated the efficacy and safety of baricitinib monotherapy in a North American phase III trial (BREEZE-ADS) of adults with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy.

There was a total of 440 patients were randomized in a 1:1:1 ratio to baricitinib 1 mg, baricitinib 2 mg, or placebo once daily. Experts then identified the number of patients achieving >75% reduction in the Eczema Area and Severity Index (EASI) at week 16 (primary endpoint) and the proportion of patients achieving a validated Investigator Global Assessment (IGA) for AD score of 0 (clear) or 1 (almost clear) with >2-point improvement (secondary endpoint).

Proportion of patients achieving EASI at week 16 was 8% for placebo, 13% for baricitinib 1mg, and 30% for baricitinib 2mg, while those with a validated IGA for IDA for AD score of 0 or 1 were 5%, 13%, and 24%, correspondingly.

Moreover, safety outcomes were comparable to those of other studies on the usage of baricitinib in atopic dermatitis (AD).

However, according to researchers that short-term clinical trial results may not be generalizable to real-world settings.

 

Source: J Am Acad Dermatol 2021;85:62-70

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post